Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

On CRSP's first-quarter 2025 earnings call, investors will likely focus on the sales numbers of its new gene therapy, Casgevy.

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Its first approved product, Casgevy, was developed in collaboration with narrow-moat Vertex Pharmaceuticals to treat transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease (SCD).

Its flagship gene therapy product for treating sickle cell disease, Casgevy, faces market hurdles. However, recent political developments, including both at the White House and the Food and Drug ...

ToolGen files patent infringement lawsuit against Vertex Pharma in UK for genome editing therapy CASGEVY: Seoul, South Korea Tuesday, April 22, 2025, 15:00 Hrs [IST] ToolGen, Inc.

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...

CRISPR’s flagship achievement is Casgevy, the first FDA-approved CRISPR-based therapy that was greenlit in December 2023 for genetic blood disorders sickle cell disease (SCD) and beta-thalassemia.

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...